Drug Profile

Y-shape pegylated somatropin - Xiamen Amoytop Biotech

Alternative Names: YPEG-rhGH; YPEG-somatropin - Xiamen Amoytop Biotech

Latest Information Update: 06 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xiamen Amoytop Biotech
Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
Mechanism of Action Human growth hormone replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II/III Somatotropin deficiency

Most Recent Events

27 Sep 2022 Y-shape pegylated somatropin is still in phase-II/III trials for Somatotropin deficiency in China
31 Aug 2012 Xiamen Amoytop Biotech completes a phase I trial in Healthy volunteers in China (NCT01339182)
31 Jan 2011 Phase-I clinical trials in Somatotropin deficiency in China (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com